首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1738670

2026 年至 2032 年癌症生物治療市場（按治療類型、癌症類型、最終用戶和地區分類）

Cancer Biological Therapy Market By Type of Therapy (Monoclonal Antibodies, Cancer Vaccines), Cancer Type (Breast Cancer, Lung Cancer), End-User (Hospitals Cancer Treatment Centers), & Region for 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

癌症生物治療市場評估-2026-2032

全球癌症發生率的上升推動了對創新治療方案的需求，並刺激了癌症生物療法的應用。個人化醫療（專注於根據個人基因特徵量身訂做治療）的轉變，正在推動市場規模在2024年突破937.4億美元，到2032年估值將達到約1533.5億美元。

除此之外，生物療法的臨床成功和患者預後的改善也刺激了癌症生物療法的應用。政府對癌症研究和治療的資金投入不斷增加以及優惠政策的訂定，推動市場在 2026 年至 2032 年期間以 7% 的複合年成長率成長。

癌症生物治療市場定義/概述

癌症生物療法，也稱為生物療法或免疫療法，利用活體生物體、源自活體生物體的物質或此類物質的合成物來治療癌症。這些治療方法透過增強人體的天然防禦能力來對抗癌症，或針對參與癌症生長和進展的特定分子。生物療法的例子包括單株抗體、癌症疫苗和細胞療法。

癌症生物療法用於治療各種類型的癌症，通常與化療、放射線治療和手術等其他療法合併使用。它們尤其擅長針對特定癌細胞，同時最大限度地減少對健康細胞的損害。單株抗體可用於抑制癌細胞生長、標記癌細胞以便免疫系統摧毀，或直接將放射治療或化療輸送至癌細胞。癌症疫苗旨在刺激免疫系統攻擊癌細胞，而細胞療法（例如 CAR-T 細胞療法）則可改變患者自身的免疫細胞，使其更有效地攻擊癌症。

全球癌症發生率的不斷上升將如何導致癌症生物療法的應用增加？

全球癌症發生率的上升是癌症生物治療市場的主要驅動力。根據世界衛生組織 (WHO) 預測，到 2040 年，癌症患者數量將比 2020 年增加 60%。美國國家癌症研究所 (美國 National Cancer Institute) 的數據顯示，約有 39.5% 的人會在一生中的某個階段被診斷出癌症。癌症負擔的加重導致對生物療法等有效且有針對性的治療的需求增加。為了因應這一趨勢，默克公司於 2024 年 2 月宣布，將以新型查核點抑制劑為中心，擴展其免疫腫瘤學產品線。同樣，羅氏公司於 2024 年 4 月宣布推出一款新的個人化癌症疫苗平台，該平台將 mRNA 技術與成熟的生物療法相結合。

生物技術的進步和對癌症生物學的深入了解正在推動生物療法的創新。 2020 年至 2024 年間，美國食品藥物管理局(FDA)核准了18 種用於治療癌症的新型生物療法。根據歐洲藥品管理局的報告，2021 年至 2023 年間，癌症生物療法的臨床試驗將增加 35%。這些發展正在帶來更有效、更有針對性且副作用更少的治療方法。 2024 年 3 月，百時美施貴寶推出了一種用於治療固體癌的突破性 CAR-T 細胞療法，拓展了這種生物療法的應用範圍。 2024 年 5 月，諾華宣布針對多發性骨髓瘤的雙特異性抗體在 III 期臨床試驗中取得成功，顯示無惡化生存期顯著改善。

缺乏獲得癌症生物療法的機會或可用性是否會限制其採用？

癌症生物療法市場發展的一個重大限制是高成本。單株抗體和嵌合抗原受體-T細胞療法等生物療法的開發、生產和管理通常成本高。這些成本包括複雜的生產流程，以及需要由訓練有素的醫療保健專業人員進行專業操作和管理。這種經濟負擔可能會限制許多患者，尤其是在中低收入國家，獲得治療的機會，這給醫療保健系統和保險公司管理這些先進療法的高昂成本帶來了挑戰。

癌症生物療法的可近性和可用性不足也是一大挑戰。由於這些療法的專業性，它們可能無法在所有地區廣泛普及，尤其是在偏遠和低度開發地區。對先進醫療基礎設施（包括專業設施和訓練有素的醫護人員）的需求進一步限制了生物療法的普及。此外，監管核准和市場進入障礙可能會延遲新治療方法的普及，影響這些治療方法及時送達有需要的患者。

癌症生物療法可能引起嚴重的副作用，例如細胞激素釋放症候群 (CRS) 和意外的免疫反應。這些副作用需要密切監測，並使治療通訊協定變得複雜，這對臨床醫生平衡療效和安全性提出了挑戰。嚴重的副作用可能會使患者虛弱無力，並給實施生物療法的醫護人員帶來額外的挑戰。

Increasing global prevalence of cancer boosts demand for innovative treatment options is propelling the adoption of cancer biological therapy. The shift towards personalized medicine, focusing on treatments tailored to individual genetic profiles is driving the market size surpass USD 93.74 Billion valued in 2024 to reach a valuation of around USD 153.35 Billion by 2032.

In addition to this, clinical success and improved patient outcomes with biological therapies are spurring up the adoption of cancer biological therapy. Increased government funding and favorable policies for cancer research and treatment is enabling the market to grow at a CAGR of 7% from 2026 to 2032.

Cancer Biological Therapy Market: Definition/ Overview

Cancer biological therapy, also known as biotherapy or immunotherapy, involves the use of living organisms, substances derived from living organisms, or synthetic versions of such substances to treat cancer. These therapies work by enhancing the body's natural defenses to fight cancer or by targeting specific molecules involved in cancer growth and progression. Examples of biological therapies include monoclonal antibodies, cancer vaccines, and cell-based therapies.

Cancer biological therapies are used to treat various types of cancer, often in combination with other treatments such as chemotherapy, radiation, and surgery. They are particularly effective in targeting specific cancer cells while minimizing damage to normal cells. Monoclonal antibodies can be used to block cancer cell growth, mark cancer cells for destruction by the immune system, or deliver radiation or chemotherapy directly to cancer cells. Cancer vaccines aim to stimulate the immune system to attack cancer cells, and cell-based therapies, such as CAR T-cell therapy, involve modifying a patient's own immune cells to target cancer more effectively.

How will Rising Global Cancer Prevalence Increase Adoption of Cancer Biological Therapy?

The rising global cancer prevalence is a primary driver of the cancer biological therapy market. According to the World Health Organization, cancer cases are projected to increase by 60% by 2040 from 2020 levels. The U.S. National Cancer Institute reported that approximately 39.5% of people will be diagnosed with cancer at some point in their lives. This increasing burden has led to greater demand for effective and targeted treatments like biological therapies. In response to this trend, Merck announced in February 2024 the expansion of its immuno-oncology pipeline, focusing on novel checkpoint inhibitors. Similarly, Roche introduced a new personalized cancer vaccine platform in April 2024, combining mRNA technology with their established biological therapies.

Advancements in biotechnology and a deeper understanding of cancer biology are fueling innovation in biological therapies. The U.S. Food and Drug Administration (FDA) approved 18 new biological therapies for cancer treatment between 2020 and 2024. A report from the European Medicines Agency showed a 35% increase in biological therapy clinical trials for cancer from 2021 to 2023. These developments are leading to more effective and targeted treatments with fewer side effects. In March 2024, Bristol Myers Squibb unveiled a groundbreaking CAR-T cell therapy for solid tumors, expanding the application of this biological approach. Novartis announced in May 2024 the successful phase III trial results for a bispecific antibody targeting multiple myeloma, demonstrating significant improvements in progression-free survival.

Will Lack of Accessibility and Availability of Cancer Biological Therapy Restrain Its Application?

One of the significant restraints in the cancer biological therapy market is the high cost associated with these treatments. Biological therapies, such as monoclonal antibodies and CAR T-cell therapy, are often expensive to develop, produce, and administer. The costs include not only the complex manufacturing processes but also the need for specialized handling and administration by trained healthcare professionals. This financial burden can limit accessibility for many patients, particularly in low- and middle-income countries, and poses a challenge for healthcare systems and insurance providers in managing the high expenses associated with these advanced treatments.

Lack of accessibility and availability of cancer biological therapies are also major challenges. Due to the specialized nature of these treatments, they may not be widely available in all regions, particularly in remote or underdeveloped areas. The need for sophisticated healthcare infrastructure, including specialized facilities and trained personnel, further restricts the widespread adoption of biological therapies. Additionally, regulatory approvals and market entry barriers can delay the availability of new treatments, impacting the timely delivery of these therapies to patients in need.

Cancer biological therapies can cause significant adverse effects and unintended immune responses, such as cytokine release syndrome (CRS). These side effects require careful monitoring and complicate treatment protocols, making it challenging for clinicians to balance efficacy and safety. Severe side effects can deter patients and create additional challenges for healthcare providers in managing biological treatments.

Category-Wise Acumens

Will Rise in Adoption of Monoclonal Antibodies (mAbs) Drive Cancer Biological Therapy Market?

Monoclonal antibodies (mAbs) is emerging as the leading segment in the cancer biological therapy market. According to the FDA, mAbs accounted for 35% of all cancer biological therapy approvals between 2020 and 2024. The National Cancer Institute reported that mAb therapies were used in 40% of cancer treatment regimens in the U.S. by 2023. This dominance is attributed to their high specificity and efficacy in targeting cancer cells. In February 2024, Roche announced the successful phase III trial results for a novel bispecific antibody targeting both HER2 and PD-1 in breast cancer patients. Similarly, Merck launched an advanced mAb therapy in April 2024, demonstrating improved overall survival rates in lung cancer patients.

The versatility of monoclonal antibodies in combination therapies is driving their market growth. The American Society of Clinical Oncology reported a 28% increase in clinical trials involving mAb combination therapies from 2021 to 2023. The European Medicines Agency approved 15 new mAb-based combination treatments between 2020 and 2024. This trend reflects the growing recognition of mAbs' potential to enhance treatment efficacy when used with other therapies. In March 2024, Bristol Myers Squibb introduced a groundbreaking triple combination therapy featuring two mAbs and a small molecule inhibitor for advanced melanoma. AstraZeneca partnered with a leading biotech firm in May 2024 to develop next-generation antibody-drug conjugates for multiple cancer types.

Which Factors Enhance the Use of Cancer Biological Therapy in Hospitals?

Hospitals is expected to emerge as the primary distribution channel for cancer biological therapies. According to the American Hospital Association, 72% of all cancer biological treatments were administered in hospital settings in 2023. The Centers for Medicare & Medicaid Services reported that hospital outpatient departments accounted for 65% of cancer biological therapy claims in 2024. This dominance is attributed to the complex nature of these treatments and the need for specialized care. In February 2024, the Mayo Clinic announced the expansion of its cancer biological therapy units across all major branches. Similarly, Cleveland Clinic partnered with Roche in April 2024 to establish advanced biological therapy infusion centers in its hospitals.

The rise of hospital-based cancer centers is fueling the growth of biological therapy administration. The National Cancer Institute reported a 30% increase in NCI-designated cancer centers from 2020 to 2024. A survey by the American Society of Clinical Oncology found that 80% of oncologists preferred hospital settings for administering complex biological therapies in 2023. This trend reflects the need for comprehensive care and immediate access to emergency services. In March 2024, MD Anderson Cancer Center unveiled a state-of-the-art biological therapy wing, featuring personalized treatment suites. NewYork-Presbyterian Hospital launched an integrated immunotherapy program in May 2024, centralizing all biological therapy services.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Cancer Biological Therapy Market?

North America leads the global cancer biological therapy market due to advanced healthcare infrastructure and high adoption rates. According to the National Cancer Institute, biological therapies accounted for 35% of all cancer treatments in the U.S. by 2023. The Canadian Cancer Society reported a 28% increase in biological therapy usage from 2020 to 2024. This dominance is fueled by substantial research funding and a robust biotechnology industry. In February 2024, the U.S. FDA approved a record number of 12 new cancer biological therapies. Merck, a key player, announced in April 2024 a USD 2 Billion investment to expand its biological therapy production facilities across North America.

The region's strong reimbursement policies and insurance coverage drive market growth. The Centers for Medicare & Medicaid Services reported that spending on cancer biological therapies increased by 40% between 2020 and 2024. A study by the American Cancer Society found that 85% of cancer patients had access to biological therapies through insurance in 2023. This financial support enhances patient access to advanced treatments. In March 2024, UnitedHealth Group expanded its coverage for CAR-T cell therapies, benefiting thousands of cancer patients. Roche partnered with major U.S. insurers in May 2024 to introduce innovative payment models for its portfolio of biological cancer treatments.

North America's leadership in clinical trials and personalized medicine boosts its market position. The NIH Clinical Trials database showed that 60% of global cancer biological therapy trials were conducted in North America in 2023. Health Canada reported a 25% increase in precision medicine approvals for cancer from 2021 to 2024. This focus on innovation drives the development of more effective therapies. In January 2024, Gilead Sciences launched a groundbreaking personalized neoantigen therapy in the U.S. market. Bristol Myers Squibb announced in June 2024 the successful completion of the largest pan-cancer immunotherapy trial to date, conducted across multiple North American centers.

Will Increasing Cancer Prevalence Enhance Adoption of Cancer Biological Therapy in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the cancer biological therapy market due to increasing cancer prevalence and improving healthcare infrastructure. According to the World Health Organization, cancer cases in Asia are projected to increase by 35% from 2020 to 2030. China's National Cancer Center reported a 25% rise in biological therapy adoption from 2021 to 2023. This growth is driven by government initiatives and rising healthcare expenditure. In February 2024, the Indian Council of Medical Research announced a $500 million investment in cancer biological therapy research. Japan's Ministry of Health approved 8 new cancer biological therapies in 2023, marking a 40% increase from the previous year.

Expansion of local biopharmaceutical companies and partnerships with global players are fueling market growth. The China National Medical Products Administration reported a 30% increase in domestic cancer biological therapy approvals between 2020 and 2024. South Korea's Ministry of Food and Drug Safety noted a 45% growth in biological therapy clinical trials from 2022 to 2024. These developments are enhancing the region's capacity for advanced cancer treatments. In March 2024, BeiGene partnered with Novartis to expand its biological therapy portfolio across Asia. Singapore-based Tessa Therapeutics raised $200 million in April 2024 to advance its CAR-T cell therapy pipeline for solid tumors. At the forefront, the availability of local vendors offering competitive pricing cloud-based solutions increase the accessibility and availability of Cancer Biological Therapy to businesses of all sizes, driving wider adoption.

Competitive Landscape

The cancer biological therapy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the cancer biological therapy market include:

Bristol-Myers Squibb
Merck & Co., Inc.
Roche Holding AG
Novartis International AG
AstraZeneca
Pfizer, Inc.
Amgen, Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Johnson & Johnson
Sanofi S.A.
Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
Gilead Sciences, Inc.
AbbVie, Inc.
Biogen, Inc.
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals, Inc.
Seagen, Inc.
Incyte Corporation
Adaptimmune Therapeutics plc.

Latest Developments

In September 2023, Novartis received FDA approval for a next-generation targeted therapy for breast cancer, marking a significant advancement in precision medicine and biological treatments.
In August 2023, AstraZeneca announced a collaboration with a leading research institute to explore the use of gene editing technologies in developing new biological therapies for lung cancer.